Wednesday, January 11, 2017 1:06:30 PM
Trump appears ready to deal a major blow to the FDA's regulatory powers. Here are two stocks that would benefit enormously from such a move.
George Budwell
( TMFGBudwell)
Jan 11, 2017 at 10:02AM
President-elect Donald Trump's views on the FDA and its role as a gatekeeper for new medicines remain shrouded in mystery roughly two weeks before his inauguration. But the decision to include the controversial billionaire and PayPal co-founder Peter Thiel in his transition team does offer some insight that may help biotech investors position themselves for the coming sea change.
According to various reports, Thiel was instrumental in advancing the candidacy of the staunch libertarian Jim O'Neill for the next commissioner of the Food and Drug Administration last month. The short story is that O'Neill is a policy guru who's previously floated the radical idea of allowing the free market, and not the FDA, to assess the effectiveness of new medicines. Trump thus appears deadly serious about reducing the FDA's regulatory rigor as a way to boost innovation in the biotech industry.
If unprecedented levels of deregulation for the pharmaceutical industry are indeed coming down the pike, I think investors may want to ratchet up their appetite for risk by checking out small biotechs like Amarin Corp. ( NASDAQ:AMRN)and( NASDAQ:AMRN)Inovio Pharmaceuticals ( NASDAQ:INO) right now. Here's why.
Trump's plan to tamp down the FDA's regulatory powers would be welcome news for this biopharmaAmarin is a small-cap Irish biopharma that sells the FDA-approved omega-3 medication Vascepa, indicated for patients with severely elevated triglyceride levels. The reason this stock is worth checking out right now is because Vascepa's tremendous commercial potential has undeniably been hampered by the FDA's current regulatory guidelines.
Since the drug's launch in 2013, for example, Vascepa has made respectable inroads into both the prescription omega-3 and non-statin prescription lipid therapy markets. But the drug still has a long way to go before it comes close to maxing out its commercial potential in either of these multi-billion dollar markets:
The backstory is that the FDA initially rejected the drug's supplemental new drug application, which would have included patients with only moderately high triglycerides in its list of approved uses, which slowed its commercial uptake. After a lengthy court battle, Amarin eventually won the right to talk to doctors about off-label uses for Vascepa, but the company still has to stay within the strict bounds of the drug's FDA-vetted clinical dataset.
The point is that Trump's plan to turn the industry on its head from a regulatory standpoint could open the door for Amarin to market Vascepa broadly within the vast lipid therapy market, without even having to complete its ongoing cardiovascular outcomes trial.
If effectiveness isn't an issue, this DNA vaccine maker is grossly undervaluedInovio Pharmaceuticals is striving to bring the first DNA-based vaccine or immunotherapy to market in the United States. The problem is that Inovio's platform, along with all other DNA vaccines to date, hasn't produced the type of clear cut effectiveness that warrants approval.
To get over this hurdle, Inovio has introduced novel delivery methods, such as the Cellectra 5PSP immunotherapy delivery device, and proposed the use of immune activators in conjunction with its DNA vaccines. However, the fact remains that this biotech has yet to advance even a single product candidate into late-stage development since its inception over 16 years ago, which certainly hasn't helped the performance of its share price:
How could a Trump-directed FDA change Inovio's outlook? Inovio has completed a Phase 2 trial for its lead product candidate, VGX-3100, as a treatment for cervical dysplasia, where the vaccine produced a favorable safety profile and an intriguing efficacy signal.
So while it may sound outlandish to those who have watched the FDA repeatedly reject drugs with robust clinical programs, VGX-3100 may actually be good to go based on its Phase 2 safety data under a Trump administration.
The key is going to be Trump's ability to knock down the 1962 Kefauver-Harris Amendment requiring drug manufacturers to demonstrate experimental products to be both safe and effective prior to approval. After all, his administration appears keen to transition to a regulatory framework that favors "real world" evidence of a drug's effectiveness -- evidence that people like Jim O'Neill believe can be gathered after a drug is already on the market.
Take-home messageWhile nothing is set in stone in terms of Trump's plans for the FDA, Jim O'Neill's candidacy for FDA commissioner is a sure sign that major changes are coming. And a weakened FDA would very likely be a boon for smaller companies like Amarin and Inovio that have struggled to meet the agency's standards in the past.
George Budwell has no position in any stocks mentioned. The Motley Fool owns shares of and recommends PayPal Holdings. The Motley Fool has a disclosure policy.
http://www.fool.com/investing/2017/01/11/more-innovation-less-regulation-3-biotech-stocks-t.aspx
Recent INO News
- INOVIO to Present at Upcoming Scientific Conference • PR Newswire (US) • 09/17/2024 08:30:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/13/2024 10:22:02 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 10:06:54 AM
- INOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights • PR Newswire (US) • 08/08/2024 08:05:00 PM
- INOVIO Reports Inducement Grant Under Inducement Plan • PR Newswire (US) • 08/01/2024 08:05:00 PM
- Inovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107 • PR Newswire (US) • 07/25/2024 08:05:00 PM
- INOVIO to Report Second Quarter 2024 Financial Results on August 8, 2024 • PR Newswire (US) • 07/25/2024 12:00:00 PM
- INO-3107 Awarded the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway • PR Newswire (US) • 07/11/2024 12:00:00 PM
- INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer • PR Newswire (US) • 07/02/2024 08:05:00 PM
- INOVIO Reports Inducement Grant Under Inducement Plan • PR Newswire (US) • 07/01/2024 08:00:00 PM
- INOVIO Added to Russell 2000® Index Effective July 1, 2024 • PR Newswire (US) • 07/01/2024 12:00:00 PM
- INOVIO to Participate in Virtual Fireside Chat Hosted by Stephens Inc. • PR Newswire (US) • 06/04/2024 12:00:00 PM
- INOVIO Reports Inducement Grants Under Inducement Plan • PR Newswire (US) • 05/31/2024 08:48:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2024 08:01:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:51:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:51:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:51:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:51:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:50:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:50:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:49:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 09:13:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 09:12:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 09:11:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 09:10:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM